🔗 Visit the ClinicalTrials.gov page for NCT00345163
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. | J Clin Oncol | 2009 | 14.15 |
| 2 | Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. | Neuro Oncol | 2011 | 1.95 |
| 3 | Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. | Radiology | 2013 | 1.55 |
| 4 | EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance. | Curr Mol Pharmacol | 2010 | 1.29 |
| 5 | Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas. | Curr Cancer Drug Targets | 2010 | 1.07 |
| 6 | Targeted therapy in the treatment of malignant gliomas. | Onco Targets Ther | 2009 | 0.78 |
| 7 | Current status and future directions of anti-angiogenic therapy for gliomas. | Neuro Oncol | 2015 | 0.77 |
| 8 | Bevacizumab for glioblastoma-a promising drug or not? | Cancers (Basel) | 2013 | 0.77 |